Skip to main content
OpenTrials
Completed

NCT Number: NCT07422233

Evaluation of Levetiracetam's Effectiveness and Tolerability for Treating Epilepsy in Older Adults

This prospective interventional study was conducted between 2023 and 2025 at the Department of Neurology of Bouali Sina Hospital. Consecutive elderly patients presenting with epilepsy were screened for eligibility. The diagnosis of epilepsy was confirmed by the treating neurologist. The patients underwent treatment with levetiracetam. Primary and secondary outcomes were investigated as was explained before.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Elderly Nervous System Diseases

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Mazandaran University of medical sciences

Sari, Mazandaran, 4815733971, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥60 years
  • Diagnosis of epilepsy

Exclusion criteria

  • Chronic kidney disease requiring dialysis
  • History of psychotic disorders or current use of anxiolytic, antidepressant, or antipsychotic medications
  • Current use of antiseizure medications for any reason

Treatment and study plan

Oral Levetiracetam

Drug

Treatment with levetiracetam tablets

Primary outcomes

  1. Seizure free rate

    Time frame: 12 months

    The rate of patients who stayed seizure-free after drug initiation

  2. Retention rate

    Time frame: 12 months

    The rate of patients who continue taking drug

  3. Time to first seizure

    Time frame: at occurrence of first seizure

    The interval between starting drug and recurrence of seizure

  4. Time to withdrawal

    Time frame: the day that the patient stops taking drug

    The interval between starting drug and stoping its use

Secondary outcomes

  1. Tolerability rate

    Time frame: 12 months

    the rate of patients that forfeit participation in the study due to adverse effects

Sponsors and collaborators

Lead sponsor

Nasim Tabrizi

Other

Registry information

Official study title

Investigation of Efficacy and Tolerability of Levetiracetam for Epilepsy in Elderly

Acronym: LEVEL

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Feb 19, 2026
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.